Združene države Amerike - angleščina - NLM (National Library of Medicine)

mission pharmacal company - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 5 meq - 1.1 renal tubular acidosis (rta) with calcium stones potassium citrate is indicated for the management of renal tubular acidosis [see clinical studies (14.1)]. 1.2 hypocitraturic calcium oxalate nephrolithiasis of any etiology potassium citrate is indicated for the management of hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14.2)]. 1.3 uric acid lithiasis with or without calcium stones potassium citrate is indicated for the management of uric acid lithiasis with or without calcium stones [see clinical studies (14.3)]. urocit ® -k is contraindicated: - in patients with hyperkalemia (or who have conditions pre-disposing them to hyperkalemia), as a further rise in serum potassium concentration may produce cardiac arrest. such conditions include: chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, extensive tissue breakdown or the administration of a potassium-sparing agent (such as triamterene, spironolactone or amiloride). - in patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. - in patients with peptic ulcer disease because of its ulcerogenic potential. - in patients with active urinary tract infection (with either urea-splitting or other organisms, in association with either calcium or struvite stones). the ability of urocit ® -k to increase urinary citrate may be attenuated by bacterial enzymatic degradation of citrate. moreover, the rise in urinary ph resulting from urocit ® -k therapy might promote further bacterial growth. - in patients with renal insufficiency (glomerular filtration rate of less than 0.7 ml/kg/min), because of the danger of soft tissue calcification and increased risk for the development of hyperkalemia. 8.1 pregnancy animal reproduction studies have not been conducted. it is also not known whether urocit-k can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. urocit-k should be given to a pregnant woman only if clearly needed. 8.3 nursing mothers the normal potassium ion content of human milk is about 13 meq/l. it is not known if urocit-k has an effect on this content. urocit-k should be given to a woman who is breastfeeding only if clearly needed. 8.4 pediatric use safety and effectiveness in children have not been established.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

cypress pharmaceutical, inc. - potassium citrate (unii: ee90oni6ff) (anhydrous citric acid - unii:xf417d3psl), citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl) - potassium citrate 3.3 g - cytra-k crystals is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. in addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. it is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. cytra-k crystals is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. cytra-k crystals alkalinizes the urine without producing a systemic alkalosis in recommended dosage. it is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. potassium cit

Združene države Amerike - angleščina - NLM (National Library of Medicine)

unit dose services - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1. for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g. digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients h

Združene države Amerike - angleščina - NLM (National Library of Medicine)

pegasus laboratories, inc. - potassium citrate (unii: ee90oni6ff) (potassium cation - unii:295o53k152) - potassium citrate 675 mg

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc. - bismuth subcitrate potassium (unii: r3o80h60kx) (bismuth - unii:u015tt5i8h), metronidazole (unii: 140qmo216e) (metronidazole - unii:140qmo216e), tetracycline hydrochloride (unii: p6r62377kv) (tetracycline - unii:f8vb5m810t) - bismuth subcitrate potassium 140 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of pylera and other antibacterial drugs, pylera should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. pylera in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate h. pylori . the eradication of helicobacter pylori has been shown to reduce the risk of duodenal ulcer recurrence. do not administer methoxyflurane to patients taking pylera. the concurrent use of tetracycline hydrochloride, a component of pylera, with methoxyflurane has been reported to resu

Združene države Amerike - angleščina - NLM (National Library of Medicine)

atlantic biologicals corp. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 20 meq in 15 ml - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics pregnancy category c animal reproduction studies have not been conducted with potassium chloride. it is unlikely that potassium supplementation that does not lead to hyperkalemia would have an adverse effect on the fetus or would affect reproductive capacity. the normal potassium ion content of human milk is about 13 meq per liter. since oral potassium becomes part of the body potassium pool, so long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. the safety and effectiveness of potassium chloride have been demonstrated in children with diarrhea and malnutrition from birth to18 years. clinical studies of potassium chloride did not include s

Združene države Amerike - angleščina - NLM (National Library of Medicine)

vistapharm, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 20 meq in 15 ml - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.  potassium chloride is contraindicated in patients on potassium sparing diuretics there are no human data related to use of potassium chloride during pregnancy, and animal studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human milk is about 13 meq per liter. since potassium from oral supplements such a

Združene države Amerike - angleščina - NLM (National Library of Medicine)

par pharmaceutical - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride 20 meq in 15 ml - potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. potassium chloride is contraindicated in patients on potassium sparing diuretics. there are no human data related to use of potassium chloride during pregnancy, and animal studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human milk is about 13 meq per liter. since potassium from oral supplements suc

Združene države Amerike - angleščina - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 10 meq - potassium chloride extended-release capsules are indicated for the treatment and prophylaxis of hypokalemia in adults and children with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.   potassium chloride extended-release capsules are contraindicated in patients on amiloride or triamterene.   risk summary there are no human data related to use of potassium chloride extended-release capsules during pregnancy and animal reproductive studies have not been conducted.  potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm.   the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respecti

Združene države Amerike - angleščina - NLM (National Library of Medicine)

vitruvias therapeutics - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698) - potassium chloride extended-release tablets is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human milk